Zydus Lifesciences Limited
₹1,244.00+₹58.00 (+4.9%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹90,637 Cr
- P/E
- 18.8x
- EV / EBITDA
- 18.4x
- Revenue
- ₹15,116 Cr
- Net margin
- 31.8%
- ROCE
- 18.5%
Price chart
Technical chartScreen technicals →+26.1% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- +6.9%
- 3M
- +11.5%
- 6M
- +39.5%
- 1Y
- +26.1%
- 5Y
- +152.7%
52-week range
Day change +₹58.00 (+4.9%) from ₹1,186 to ₹1,244 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in ZYDUSLIFE, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Strong 5-year net profit CAGR of 19.5%
Concerns1
- Negative free cash flow (₹1390 Cr)
Rule-based from financial data. Not advice.
About the company
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products.
Read moreShow less
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses, as well as in the therapeutic areas of pain management, neurology, metabolic disorder, and neurology. In addition, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. Further, it develops and markets products for orthopaedic surgery, including pathologies affecting the hip and knee. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.
- Sector
- Healthcare
- Shares outstanding
- 101 Cr shares
- ISIN
- INE010B01027
- BSE code
- 532321
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹90,637 Cr
- P/E
- 18.8x
- P/B
- 4.2x
- EV / EBITDA
- 18.4x
- EV / Sales
- 8.7x
- P/S
- 8.4x
- Earnings yield
- 5.3%
- 52-week high
- ₹1,244.00
- 52-week low
- ₹860.55
Profitability
- Operating margin
- 37.5%
- Net margin
- 31.8%
- EBITDA margin
- 47.5%
- ROE
- 21.9%
- ROCE
- 18.5%
- ROA
- 14.3%
- Dividend payout
- 9.0%
- Tax rate
- 19.0%
- Other income, % of PBT
- 25.4%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹15,116 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 39.7%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 11.3%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹5,135 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 83.5%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 67.8%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 19.5%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹2,000 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 85.5%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹5.00 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 17.1%
Solvency and efficiency
- Current ratio
- 8.71
- Debt / Equity
- 0.39
- Debt / Assets
- 0.26
- Debt / EBITDA
- 1.20
- Interest coverage
- 10.38
- Financial leverage
- 1.53
- CFO / Net profit
- 0.58
- Cash / Market cap
- 13.0%
- Cash per share
- ₹117.28
- Asset turnover
- 0.45
- Fixed asset turnover
- 2.48
- Capital intensity
- 0.40
- Debtor days
- 160 days
- Inventory turnover
- 1.87
- Cash conversion cycle
- 227 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹38 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹7,380 Cr |
| Sales | Operating profit | ₹7,736 Cr |
| Operating profit | Interest | ₹464 Cr |
| Operating profit | Depreciation | ₹524 Cr |
| Operating profit | Profit before tax | ₹6,748 Cr |
| Other income | Profit before tax | ₹696 Cr |
| Profit before tax | Tax and other | ₹1,670 Cr |
| Profit before tax | Net profit | ₹5,775 Cr |
Revenue and net profit
Revenue grew 39.7% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹7,780 Cr | ₹1,476 Cr |
| FY2022 | ₹7,837 Cr | ₹858 Cr |
| FY2023 | ₹8,732 Cr | ₹1,529 Cr |
| FY2024 | ₹10,819 Cr | ₹3,442 Cr |
| FY2025 | ₹15,116 Cr | ₹5,775 Cr |
Cash flows
FY2025: ₹3,114 Cr from operations, -₹1,390 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹2,227 Cr | -₹487 Cr |
| FY2022 | ₹1,272 Cr | ₹1,858 Cr |
| FY2023 | ₹1,078 Cr | -₹881 Cr |
| FY2024 | ₹2,000 Cr | ₹168 Cr |
| FY2025 | ₹3,114 Cr | -₹1,390 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹15,116 Cr+39.7%1Y
- Net profit
- ₹5,775 Cr+67.8%1Y
- Cash from operations
- ₹3,114 Cr
- Free cash flow
- -₹1,390 Cr-927.4%1Y
- Revenue CAGR, 5Y
- 11.3%
- EBITDA CAGR, 5Y
- 17.6%
- Net profit CAGR, 5Y
- 19.5%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹15,116 Cr | ₹7,736 Cr | — | ₹5,775 Cr | ₹3,114 Cr | -₹1,390 Cr | 27.3% | +39.7% | +67.8% |
Monthly returns
Month-by-month returns of ZYDUSLIFE across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹32,317 Cr |
| Equity capital | ₹101 Cr |
| Reserves | ₹21,090 Cr |
| Borrowings | ₹8,342 Cr |
| Other liabilities | ₹2,785 Cr |
| Assets | ₹32,317 Cr |
| Fixed assets | ₹4,202 Cr |
| Capital work in progress | ₹1,188 Cr |
| Investments | ₹11,492 Cr |
| Other assets | ₹15,435 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
ZYDUSLIFE trades at 18.8x earnings against a peer median of 52.6x (a 64% discount).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Zydus Lifesciences LimitedZYDUSLIFEthis companyP/E ↓ discount | ₹90,637 Cr | 18.8x | 4.2x | 21.9% | 18.4x |
| Cipla Ltd.CIPLA | ₹1.2 L Cr | 22.5x | 3.5x | 14.6% | 19.3x |
| Apollo Hospitals Enterprises Ltd.APOLLOHOSP | ₹1.1 L Cr | 75.0x | 11.3x | 13.1% | 54.4x |
| Max Healthcare Institute LimitedMAXHEALTH | ₹1.0 L Cr | 144.0x | 11.8x | 8.9% | 96.8x |
| Lupin LtdLUPIN | ₹99,475 Cr | 18.6x | 3.7x | 11.3% | 27.4x |
| Dr. Reddy's Laboratories Ltd.DRREDDY | ₹99,417 Cr | 18.4x | 3.2x | 17.9% | 14.3x |
| Mankind Pharma LimitedMANKIND | ₹91,284 Cr | 54.8x | 5.9x | 19.3% | 34.3x |
| Alkem Laboratories LimitedALKEM | ₹70,090 Cr | 31.4x | 5.1x | 16.6% | 33.0x |
| Fortis Healthcare LtdFORTIS | ₹68,497 Cr | 370.0x | 7.4x | 2.2% | 160.8x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
ZYDUSLIFE since 1 January, against earlier years.
Historical volatility
ZYDUSLIFE's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 30.0% |
| FY2022 | 25.0% |
| FY2023 | 28.0% |
| FY2024 | 38.0% |
| FY2025 | 51.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹15,116 Cr |
| Costs | |
| Interest | ₹464 Cr |
| Expenses | ₹7,380 Cr |
| Operating profitOperating Profit | ₹7,736 Cr |
| Other income and charges | |
| Profit before tax | ₹7,445 Cr |
| Tax | |
| Net profitNet Profit | ₹5,775 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹32,317 Cr |
| Equity capitalEquity Capital | ₹101 Cr |
| Reserves | ₹21,090 Cr |
| Borrowings | ₹8,342 Cr |
| Other liabilitiesOther Liabilities | ₹2,785 Cr |
| AssetsTotal Assets | ₹32,317 Cr |
| Fixed assetsFixed Assets | ₹4,202 Cr |
| Capital work in progressCWIP | ₹1,188 Cr |
| Investments | ₹11,492 Cr |
| Other assetsOther Assets | ₹15,435 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹3,114 Cr |
| Investing cash flowCash from Investing Activity | -₹4,504 Cr |
| Financing cash flowCash from Financing Activity | ₹1,384 Cr |
| Change in cashNet Cash Flow | -₹5 Cr |
Learn while you research
Academy chapters picked for Zydus Lifesciences Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Growth Investing40% revenue growth is in the top tier, learn how to value growth.7 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read